RxDoctor Payments DataLook up a doctor →

Robert Sheppard, MD

Clinical Cardiac Electrophysiology · St Petersburg, FLNPI 1578525937

Payments from drug & device makers

$287,997in general payments, 2019–2025

Across 852 payments — averaging $338.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$233K
  • Medtronic$16K
  • Biotronik Inc.$11K
  • Abbott$9K
  • Atricure, Inc.$5K
  • Boston Scientific$4K
  • plus $11K from 36 others

What the payments were for

  • Consulting fees$2,7755%
  • Speaking & faculty fees$4,7259%
  • Travel & lodging$15,52829%
  • Food & beverage$30,24157%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$287,997 in reported general payments places this provider in the 85th percentile of 249 clinical cardiac electrophysiology providers in Florida.

See all clinical cardiac electrophysiology providers in Florida

Medicare billing

Part B allowed, 2024
$194,774
Medicare patients
715
Services billed
2,331

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban232$261,521
XareltoRivaroxaban65$80,936
MultaqDronedarone Hcl35$37,120
FarxigaDapagliflozin Propanediol12$12,018
Dofetilide27$9,256
SotalolSotalol Hcl87$2,672
Amiodarone Hcl97$2,497
Flecainide Acetate47$2,432
Diltiazem 24hr Er (Cd)Diltiazem Hcl59$2,317
Metoprolol Succinate114$1,720
Digoxin45$1,052
Propafenone Hcl12$893
Metoprolol Tartrate69$451
Carvedilol36$199
Lisinopril23$134

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$343$261,521232 claims
Johnson & JohnsonXarelto$205$80,93665 claims
Sanofi-aventis U.S. LLCMultaq$276$37,12035 claims
AstraZenecaFarxiga$69$12,01812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 249 clinical cardiac electrophysiology providers in Florida.

Other clinical cardiac electrophysiology in St Petersburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →